Dizal (Jiangsu) Pharmaceutical Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2018
Period Ending	Sep '24 Sep 5, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2018
Market Capitalization	14,872	19,530	16,030	14,959	-	-	Upgrade
Market Cap Growth	8.12%	21.84%	7.16%	-	-	-	Upgrade
Enterprise Value	14,743	18,891	14,518	14,805	-	-	Upgrade
Last Close Price	35.78	47.85	39.37	37.01	-	-	Upgrade
PE Ratio	-	-17.59	-21.63	-19.90	-	-	Upgrade
PS Ratio	49.86	213.94	-	1454.37	-	-	Upgrade
PB Ratio	24.42	23.01	9.12	6.07	-	-	Upgrade
P/FCF Ratio	-17.63	-19.53	-23.67	-29.84	-	-	Upgrade
P/OCF Ratio	-18.48	-20.18	-26.57	-30.39	-	-	Upgrade
EV/Sales Ratio	50.00	206.93	-	1439.37	-	-	Upgrade
EV/EBITDA Ratio	-14.37	-16.92	-19.26	-23.24	-	-	Upgrade
EV/EBIT Ratio	-13.88	-16.35	-18.32	-21.95	-	-	Upgrade
EV/FCF Ratio	-16.97	-18.89	-21.44	-29.53	-	-	Upgrade
Debt / Equity Ratio	1.10	0.48	0.05	0.04	-	-	Upgrade
Debt / FCF Ratio	-0.79	-0.41	-0.13	-0.18	-	-	Upgrade
Asset Turnover	0.17	0.05	-	0.01	0.03	0.06	Upgrade
Inventory Turnover	0.54	0.54	-	-	-	-	Upgrade
Quick Ratio	1.69	1.78	5.70	9.82	5.88	1.30	Upgrade
Current Ratio	1.87	2.03	5.93	9.96	6.06	1.38	Upgrade
Return on Equity (ROE)	-104.24%	-84.98%	-34.87%	-37.83%	-76.72%	-89.69%	Upgrade
Return on Assets (ROA)	-40.12%	-40.35%	-20.52%	-21.46%	-52.76%	-44.46%	Upgrade
Return on Capital (ROIC)	-48.20%	-46.54%	-22.54%	-23.23%	-62.42%	-56.68%	Upgrade
Earnings Yield	-6.38%	-5.67%	-4.59%	-4.48%	-	-	Upgrade
FCF Yield	-5.84%	-5.12%	-4.22%	-3.35%	-	-	Upgrade
Buyback Yield / Dilution	-1.30%	-0.70%	-12.29%	-0.07%	-	-	Upgrade
Total Shareholder Return	-1.30%	-0.70%	-12.29%	-0.07%	-	-	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.